1st Circ. Won't Revive Karyopharm Investors' Stock-Drop Suit

By Dave Simpson (August 5, 2022, 9:18 PM EDT) -- The First Circuit won't revive a putative securities fraud class action claiming that Karyopharm Therapeutics Inc. executives gave an overly rosy assessment of negative drug trial results, ruling Friday that investors failed to plausibly allege that the drugmaker materially misrepresented those results....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!